Sign In
Buy SOPH
$5.67
-0.0900 (-1.56%)
At Close: Jul 31, 2026
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025
08:00am, Tuesday, 22'nd Jul 2025
BOSTON and ROLLE, Switzerland , July 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its
SOPHiA GENETICS SA (NASDAQ:SOPH) Shares Sold by Squarepoint Ops LLC
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC lowered its position in SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exc
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript
03:05am, Saturday, 10'th May 2025
SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Ch
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
08:55am, Tuesday, 06'th May 2025
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
SOPHiA GENETICS Reports First Quarter 2025 Results
06:45am, Tuesday, 06'th May 2025
BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
12:00pm, Monday, 28'th Apr 2025
BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025
08:00am, Tuesday, 22'nd Apr 2025
BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release it
The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md.
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 21'st Mar 2025
SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
09:00am, Tuesday, 18'th Mar 2025
BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone:
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript
02:32pm, Tuesday, 04'th Mar 2025
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Execut
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
08:55am, Tuesday, 04'th Mar 2025
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago.
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results
06:45am, Tuesday, 04'th Mar 2025
BOSTON and ROLLE, Switzerland , March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for i
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
04:00am, Monday, 24'th Feb 2025
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pionee
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025
08:30am, Tuesday, 18'th Feb 2025
BOSTON and ROLLE, Switzerland , Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its
